巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    CTI BioPharma Corp

    CTIC
    5.400
    0.290
    5.10%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・CTI BioPharma Corp - 延遲價格・最後更新於 16/08 10:00
    最高位
    5.700
    最低位
    5.370
    開市價
    --
    前收市價
    5.690
    成交量(千)
    294.07
    成交額(百萬)
    12.68
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    617.68
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    7.800 - 1.430
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    CTI BioPharma Corp
    證券代碼
    CTIC.US
    所屬板塊
    Biotechnology
    公司業務
    CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
    發行量
    99917628
    公司總部
    3101 Western Avenue, Suite 800
    公司網址
    https://www.ctibiopharma.com
    公司電郵
    invest@ctibiopharma.com
    公司電話
    +1 206 282-7100
    暫無內容

    關於

    CTI BioPharma Corp(CTIC.US)所屬的行業板塊為Biotechnology。
    CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
    詳細公司背景可參考: https://www.ctibiopharma.com